Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility

Mary Lynn Davis-Ajami,1 Jun Wu,2 Katherine Downton,3 Emilie Ludeman,3 Virginia Noxon4 1Organizational Systems and Adult Health, University of Maryland School of Nursing, Baltimore, MD, USA; 2South Carolina College of Pharmacy, University of South Carolina, Greenville, SC, USA; 3Health Sciences and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/000e287396fa4c429cff4d0b97cbb272
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:000e287396fa4c429cff4d0b97cbb272
record_format	dspace
spelling	oai:doaj.org-article:000e287396fa4c429cff4d0b97cbb2722021-12-02T08:21:09ZEpoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility1177-5475https://doaj.org/article/000e287396fa4c429cff4d0b97cbb2722014-04-01T00:00:00Zhttp://www.dovepress.com/epoetin-zeta-in-the-management-of-anemia-associated-with-chronic-kidne-a16485https://doaj.org/toc/1177-5475 Mary Lynn Davis-Ajami,1 Jun Wu,2 Katherine Downton,3 Emilie Ludeman,3 Virginia Noxon4 1Organizational Systems and Adult Health, University of Maryland School of Nursing, Baltimore, MD, USA; 2South Carolina College of Pharmacy, University of South Carolina, Greenville, SC, USA; 3Health Sciences and Human Services Library, University of Maryland, Baltimore, MD, USA; 4Department of Clinical Pharmacy and Outcomes Science, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA Abstract: Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as well as for symptomatic renal anemia in adult patients with renal insufficiency not yet on dialysis. Currently, epoetin zeta can be administered either subcutaneously or intravenously to correct for hemoglobin concentrations ≤10 g/dL (6.2 mmol/L) or with dose adjustment to maintain hemoglobin levels at desired levels not in excess of 12 g/dL (7.5 mmol/L). This review article focuses on epoetin zeta indications in chronic kidney disease, its use in managing anemia of renal origin, and discusses its pharmacology and clinical utility. Keywords: biosimilar, chronic kidney disease, epoetin alfa, erythropoiesis, renal anemia, Retacrit®Davis-Ajami MLWu JDownton KLudeman ENoxon VDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2014, Iss default, Pp 155-167 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Davis-Ajami ML Wu J Downton K Ludeman E Noxon V Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
description	Mary Lynn Davis-Ajami,1 Jun Wu,2 Katherine Downton,3 Emilie Ludeman,3 Virginia Noxon4 1Organizational Systems and Adult Health, University of Maryland School of Nursing, Baltimore, MD, USA; 2South Carolina College of Pharmacy, University of South Carolina, Greenville, SC, USA; 3Health Sciences and Human Services Library, University of Maryland, Baltimore, MD, USA; 4Department of Clinical Pharmacy and Outcomes Science, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA Abstract: Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as well as for symptomatic renal anemia in adult patients with renal insufficiency not yet on dialysis. Currently, epoetin zeta can be administered either subcutaneously or intravenously to correct for hemoglobin concentrations ≤10 g/dL (6.2 mmol/L) or with dose adjustment to maintain hemoglobin levels at desired levels not in excess of 12 g/dL (7.5 mmol/L). This review article focuses on epoetin zeta indications in chronic kidney disease, its use in managing anemia of renal origin, and discusses its pharmacology and clinical utility. Keywords: biosimilar, chronic kidney disease, epoetin alfa, erythropoiesis, renal anemia, Retacrit®
format	article
author	Davis-Ajami ML Wu J Downton K Ludeman E Noxon V
author_facet	Davis-Ajami ML Wu J Downton K Ludeman E Noxon V
author_sort	Davis-Ajami ML
title	Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
title_short	Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
title_full	Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
title_fullStr	Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
title_full_unstemmed	Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
title_sort	epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/000e287396fa4c429cff4d0b97cbb272
work_keys_str_mv	AT davisajamiml epoetinzetainthemanagementofanemiaassociatedwithchronickidneydiseasedifferentialpharmacologyandclinicalutility AT wuj epoetinzetainthemanagementofanemiaassociatedwithchronickidneydiseasedifferentialpharmacologyandclinicalutility AT downtonk epoetinzetainthemanagementofanemiaassociatedwithchronickidneydiseasedifferentialpharmacologyandclinicalutility AT ludemane epoetinzetainthemanagementofanemiaassociatedwithchronickidneydiseasedifferentialpharmacologyandclinicalutility AT noxonv epoetinzetainthemanagementofanemiaassociatedwithchronickidneydiseasedifferentialpharmacologyandclinicalutility
_version_	1718398522349322240

Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility

Ejemplares similares